• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

子宫内膜癌中雌激素受体（ER）、孕激素受体（PR）和HER-2/neu受体的表达及其与肿瘤组织学类型、分级和分期的关系。

Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor.

作者信息

Waqar Samina, Khan Saleem Ahmad, Sarfraz Tariq, Waqar Saba

机构信息

Dr. Samina Waqar, M.Phil. Department of Histopathology, Army Medical College/ Military Hospital, Rawalpindi, Pakistan.

Dr. Saleem Ahmad Khan, PhD. Department of Hematology, Army Medical College/ Military Hospital, Rawalpindi, Pakistan.

出版信息

Pak J Med Sci. 2018 Mar-Apr;34(2):266-271. doi: 10.12669/pjms.342.13637.

DOI:10.12669/pjms.342.13637
PMID:29805391
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5954362/
Abstract

OBJECTIVE

To study and detect immunohistochemical expression of Estrogen Receptors, Progestrone Receptors and HER-2/neu Receptors in Endometrial Carcinoma (EC) and to find their associations with histological types, grades and stages of the tumor.

METHODS

A cross sectional study of one year duration from January 2016 to January 2017 was conducted at Histopathology department of Army Medical College, Rawalpindi. A non-probability purposive sampling technique was used to include 56 cases of EC. The specimens were tested for ER, PR and HER-2/neu expression using immunohistochemical analysis. Data was analyzed in SPSS and the significance of association of expression of the receptors with histological types, grades and stages of the tumor was assessed.

RESULTS

Significant association of Her-2/neu overexpression with histological types and grades of EC was seen, whereas the association of ER and PR expression with histological types, grades and stage of EC was statistically insignificant.

CONCLUSION

It is suggested that EC showing over expression of HER2/neu with immunohistochemistry may be treated with anti HER-2/neu treatment with better chances of survival and decreased post-treatment morbidity.

摘要

目的

研究并检测子宫内膜癌（EC）中雌激素受体、孕激素受体及HER-2/neu受体的免疫组化表达情况，探讨其与肿瘤组织学类型、分级及分期的相关性。

方法

2016年1月至2017年1月，在拉瓦尔品第陆军医学院组织病理学科室开展了一项为期一年的横断面研究。采用非概率立意抽样技术纳入56例子宫内膜癌病例。运用免疫组化分析检测标本中的雌激素受体（ER）、孕激素受体（PR）及HER-2/neu表达情况。数据在SPSS软件中进行分析，评估受体表达与肿瘤组织学类型、分级及分期之间相关性的显著性。

结果

观察到HER-2/neu过表达与子宫内膜癌的组织学类型及分级存在显著相关性，而雌激素受体（ER）和孕激素受体（PR）表达与子宫内膜癌的组织学类型、分级及分期之间的相关性无统计学意义。

结论

提示免疫组化显示HER2/neu过表达的子宫内膜癌患者，采用抗HER-2/neu治疗可能具有更好的生存机会，并降低治疗后发病率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bc/5954362/0fc8dba6d4b5/PJMS-34-266-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bc/5954362/0a308bf30295/PJMS-34-266-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bc/5954362/0fc8dba6d4b5/PJMS-34-266-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bc/5954362/0a308bf30295/PJMS-34-266-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bc/5954362/0fc8dba6d4b5/PJMS-34-266-g002.jpg

相似文献

1
Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor.子宫内膜癌中雌激素受体（ER）、孕激素受体（PR）和HER-2/neu受体的表达及其与肿瘤组织学类型、分级和分期的关系。
Pak J Med Sci. 2018 Mar-Apr;34(2):266-271. doi: 10.12669/pjms.342.13637.
2
Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.巴基斯坦北部乳腺癌的形态学特征及HER-2/neu与预后标志物的关联
J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103.
3
Steroid hormone receptor association with prognostic markers in breast carcinoma in Northern Pakistan.巴基斯坦北部乳腺癌中类固醇激素受体与预后标志物的关联
J Coll Physicians Surg Pak. 2010 Mar;20(3):181-5.
4
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.乳腺癌中雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER-2/neu，即C-erb B 2）反应模式与组织学分级、肿瘤大小及淋巴结状态的比较
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.
5
Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.雌激素受体α和β以及孕激素受体A和B在人子宫内膜黏液癌中的表达。
Anticancer Res. 2007 Jul-Aug;27(4A):2027-33.
6
Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer.原发性和体外子宫内膜癌中雌激素受体、孕激素受体和 Her-2/neu 的表达。
Histol Histopathol. 2013 Jun;28(6):787-94. doi: 10.14670/HH-28.787. Epub 2012 Dec 19.
7
Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.子宫内膜样癌与浆液性乳头状子宫内膜癌的免疫组织化学对比研究
Eur J Gynaecol Oncol. 2001;22(2):122-6.
8
Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).通过自动图像分析系统ACIS III（达科公司）和ScanScope（艾派丽奥公司）评估乳腺癌Her2/neu和激素受体状态的研究
Folia Histochem Cytobiol. 2010 Jan 1;48(1):19-25. doi: 10.2478/v10042-010-0015-1.
9
Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.经皮穿刺活检标本中乳腺癌1型的表达及其与雌激素受体、孕激素受体和人表皮生长因子受体2/neu在乳腺癌中表达的关系。
Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):31-38. doi: 10.4103/IJPM.IJPM_393_16.
10
Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.乳腺髓样癌、非典型髓样癌及高级别浸润性导管癌中HER-2/neu、p53、MIB1以及雌激素受体/孕激素受体的差异扩增与过表达。
Arch Pathol Lab Med. 2003 Nov;127(11):1458-64. doi: 10.5858/2003-127-1458-DAAOON.

引用本文的文献

1
Clinico-Morphological Features and Immunohistochemical Profile of a Rare Case of Three Synchronous Primary Malignancies in the Female Genital Tract.女性生殖道罕见的三发性原发性恶性肿瘤病例的临床形态学特征及免疫组化分析
Reports (MDPI). 2024 Feb 17;7(1):14. doi: 10.3390/reports7010014.
2
Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders.内源性大麻素系统针对神经炎性自身免疫性疾病的治疗特性
Molecules. 2021 Jun 3;26(11):3389. doi: 10.3390/molecules26113389.
3
Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer.

本文引用的文献

1
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.HER2/neu 在子宫内膜癌中的作用：具有诊断挑战的有前途的治疗靶点。
Arch Pathol Lab Med. 2014 Mar;138(3):343-50. doi: 10.5858/arpa.2012-0416-RA.
2
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.子宫浆液性癌的靶向治疗：子宫内膜癌的一种侵袭性亚型
Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72.
3
Hospital-based study of endometrial cancer survival in Mumbai, India.印度孟买基于医院的子宫内膜癌生存率研究。
子宫内膜癌中的雌激素受体、孕激素受体和HER2受体标志物
J Cancer. 2020 Jan 16;11(7):1693-1701. doi: 10.7150/jca.41943. eCollection 2020.
Asian Pac J Cancer Prev. 2013;14(2):977-80. doi: 10.7314/apjcp.2013.14.2.977.
4
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.子宫浆液性癌是子宫内膜癌的一种生物学侵袭性变体，针对其的靶向治疗的发展。
Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9. doi: 10.1586/era.11.192.
5
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.美国人群中胃及胃食管交界腺癌的HER2表达：HER2评估建议方法的临床病理分析
Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):13-24. doi: 10.1097/PAI.0b013e31821c821c.
6
HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.食管腺癌中的 HER2 扩增、过表达和评分标准。
Mod Pathol. 2011 Jul;24(7):899-907. doi: 10.1038/modpathol.2011.47. Epub 2011 Apr 1.
7
Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study.雌激素受体（ER）、孕激素受体（PR）及人表皮生长因子受体2（Her-2/neu）在子宫内膜癌中的表达：一项临床病理研究
Asian Pac J Cancer Prev. 2010;11(1):215-20.
8
HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
Histopathology. 2010 Jan;56(2):269-73. doi: 10.1111/j.1365-2559.2009.03464.x.
9
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.曲妥珠单抗治疗HER2/neu过表达的晚期或复发性子宫内膜癌患者。
Int J Gynaecol Obstet. 2008 Aug;102(2):128-31. doi: 10.1016/j.ijgo.2008.04.008. Epub 2008 Jun 16.
10
Novel molecular profiles of endometrial cancer-new light through old windows.子宫内膜癌的新型分子图谱——透过旧窗口的新曙光
J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9. doi: 10.1016/j.jsbmb.2007.09.020. Epub 2007 Sep 15.